Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

NCT01473953 · Completed

Last updated 2026-05-28

This clinical trial tested the safety and tolerability of a long-acting form of liraglutide in healthy adults.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 31 people

Who can join Ages 18–55 · male only

Timeline Started 2011-10 · est. completion 2012-03

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01473953 ↗

Description as written by the study sponsor.

This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability and pharmacokinetics (exposure in the body) of liraglutide-depot in healthy subjects.

Treatments tested

liraglutide-depot Drug

Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.
placebo Drug

Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).

Main thing measured	Number of Treatment Emergent Adverse Events (TEAEs)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2, Healthy
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01473953 ↗